Tag: NYR

Nyrada cholesterol-lowering Drug study results ASX NYR PCSK9 inhibitor

Nyrada reveals encouraging cholesterol-lowering drug study results

Australian biotech Nyrada Inc (ASX: NYR) has reported encouraging pre-clinical results from its drug development program to treat patients with high cholesterol. The company today told the market t...
Nyrada ASX NYR brain injury program block calcium ion build-up NYX-104 NYX-242 NYX-1010

Nyrada announces progress in brain injury study

Nyrada (ASX: NYR) has achieved a milestone in one of its drug development programs for the treatment of brain injury, revealing its lead candidate compounds can cross the blood-brain barrier in the in...
Nyrada brain injury cholesterol lowering studies COVID-19 coronavirus ASX NYR

Nyrada advances brain injury and cholesterol lowering studies, remains unaffected by COVID-19

Nyrada (ASX: NYR) revealed this morning it was continuing to make “strong progress” in its two lead drug programs to treat brain injury and lower cholesterol. The brain injury program is using a ne...
Nyrada podcast ASX NYR James Bonnar biotechvideo

Nyrada CEO James Bonnar discusses the company’s commercialisation plans – Podcast

Junior biotech company Nyrada (ASX: NYR) was the first IPO off the mark for 2020, with the company’s stock floating on the ASX in mid-January after raising the intended maximum of A$8.5 million....
Nyrada blood cholesterol lowering drug studies ASX NYR protein PCSK9

Nyrada cholesterol-lowering drug studies validated in peer reviewed medical journal

Drug discoverer and early stage developer Nyrada (ASX: NYR) has had a significant advance made in the pre-clinical studies of its cholesterol-lowering drug program published in a medical journal. T...
Nyrada ASX IPO

Noxopharm’s US biotech subsidiary Nyrada IPO successfully raises $8.5m

Australian biotech Noxopharm’s (ASX: NOX) US spin-off Nyrada Inc (ASX: NYR) experienced strong demand in its initial public offering and will now make its ASX debut today after successfully raising $8...